Claims for Patent: 8,722,702

Summary for Patent: 8,722,702

Title:	Compounds modulating c-fms and/or c-kit activity and uses therefor
Abstract:	Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
Inventor(s):	Jiazhong Zhang, Prabha N. Ibrahim, Dean R. Artis, Ryan Bremer, Guoxian Wu, Marika Nespi, Chao Zhang
Assignee:	Daiichi Sankyo Inc
Application Number:	US13/776,547
Patent Claims:	1. A compound of Formula IIa: or a pharmaceutically acceptable salt, a tautomer or a stereoisomer thereof, wherein: A3 is —CH2— or —C(O)—; Q13 and Q14 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl; Q12 is fluoro, chloro or —CF3 M4 is —NHCH2— or —NHC(O)—; Q1a is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, —NHR41, —NR41R41, —OR41 or —S(O)2R41; and R41 at each occurrence is independently lower alkyl or cycloalkyl, wherein lower alkyl is optionally substituted with one or more fluoro; Q5 is —OR43, —CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from halogen, lower alkyl, fluoro substituted lower alkyl, —NHR43, —NR43R43, —OR43 or —S(O)2R43, wherein R43 at each occurrence is independently optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl. 2. The compound of claim 1, wherein: M4 is —NHCH2—; Q5 is —OR43, —CN, C1-3 alkyl, fluoro substituted C1-3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, —NHR43, —NR43R43, —OR43 and —S(O)2R43; and Q13 and Q14 are hydrogen. 3. The compound of claim 1, wherein: Q1a is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from halogen, lower alkyl, fluoro substituted lower alkyl, —NHR41, —NR41R41, or —OR41. 4. The compound of claim 1, wherein: Q1a is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with 1 or 2 substituents selected from fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy; and Q5 is —CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. 5. The compound of claim 4, wherein Q1a is phenyl mono substituted with chloro and Q5 is —CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. 6. The compound of claim 1, wherein Q1a is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy and Q5 is —CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. 7. The compound of claim 1, wherein: Q1a is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy and trifluoromethoxy; Q5 is fluoro, chloro, methyl, methoxy, trifluoromethyl, trifluoromethoxy, —CN, or 1-methyl-1H-pyrazole-4-yl; and Q12 is fluoro or chloro; and Q13 and Q14 are hydrogen. 8. The compound of claim 7, wherein Q1a is phenyl substituted with one chloro and Q5 is chloro, methyl, methoxy, or —CN. 9. The compound of claim 1, wherein: Q1a is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy; Q5 is chloro, methyl, methoxy, —CN, or 1-methyl-1H-pyrazole-4-yl; Q12 is fluoro or chloro; and Q13 and Q14 are hydrogen. 10. A compound of Formula III: or a pharmaceutically acceptable salt, a tautomer or a stereoisomer thereof, wherein: L4 is —CH2 or —C(O)—; R81 is selected from —CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy; R82 is hydrogen, C1-3 alkyl, fluoro substituted C2-3 alkyl, OH, C1-3 alkoxy, or fluoro substituted C1-3 alkoxy; R83 is heteroaryl, wherein the heteroaryl is optionally substituted with one or two substituents selected from halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, —NHR41, —NR41R41, —OR41 or —S(O)2R41; and R41 at each occurrence is independently lower alkyl or cycloalkyl, wherein lower alkyl is optionally substituted with one or more fluoro. 11. The compound of claim 10, wherein L4 is —CH2. 12. The compound of claim 10, wherein the heteroaryl is pyridinyl, pyrimidinyl, pyrazinyl, pyrazolyl, isoxazolyl, imidazolyl, or benzimidazolyl. 13. The compound of claim 10, wherein R83 is a heteroaryl optionally substituted with 1 or 2 substituents independently selected from fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, or cycloalkylamino. 14. The compound of claim 10, wherein R83 is a heteroaryl optionally substituted with 1 or 2 substituents independently selected from fluoro, chloro, methyl, trifluoromethyl, methoxy or morpholine. 15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of claim 1. 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier excipient and a compound of claim 10.